Sirio Pharma Cash Flow Conversion Efficiency

Latest as of June 2023: 0.035x

Sirio Pharma cash flow conversion efficiency. Based on the latest financial reports, Sirio Pharma (300791) has a cash flow conversion efficiency ratio of 0.035x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥101.61 Million ≈ $14.87 Million USD) by net assets (CN¥2.91 Billion ≈ $425.09 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Sirio Pharma (2016–2024)

Cash flow conversion efficiency of Sirio Pharma from 2016 to 2024. This chart illustrates how Sirio Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Sirio Pharma share price for real-time trading data and today's change.

Sirio Pharma Cash Flow Conversion Ratio Explained

Sirio Pharma cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Sirio Pharma Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sirio Pharma ranked by their cash flow conversion efficiency. Also see how much is Sirio Pharma worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
NPK International Inc. NYSE:NPKI	0.059x
Dongfeng Electronic Technology Co Ltd SHG:600081	0.063x
Hextar Global Bhd KLSE:5151	0.095x
Bloomin Brands Inc NASDAQ:BLMN	0.209x
Zhejiang Zhengguang Industrial Co. Ltd. SHE:301092	N/A
Besalco Sa SN:BESALCO	0.062x
Mid Penn Bancorp NASDAQ:MPB	0.032x
Medplus Health Services Limited NSE:MEDPLUS	0.159x

Annual Cash Flow Conversion Efficiency for Sirio Pharma (2016–2024)

The table below shows the annual cash flow conversion efficiency of Sirio Pharma from 2016 to 2024. Review cash generation quality of Sirio Pharma to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥2.64 Billion ≈ $386.49 Million	CN¥566.97 Million ≈ $82.97 Million	0.215x	+42.68%
2023-12-31	CN¥2.57 Billion ≈ $375.51 Million	CN¥386.08 Million ≈ $56.50 Million	0.150x	-8.63%
2022-12-31	CN¥2.70 Billion ≈ $395.32 Million	CN¥444.86 Million ≈ $65.10 Million	0.165x	+22.75%
2021-12-31	CN¥2.54 Billion ≈ $372.38 Million	CN¥341.38 Million ≈ $49.95 Million	0.134x	-8.38%
2020-12-31	CN¥2.18 Billion ≈ $319.40 Million	CN¥319.57 Million ≈ $46.76 Million	0.146x	+22.96%
2019-12-31	CN¥1.95 Billion ≈ $284.62 Million	CN¥231.60 Million ≈ $33.89 Million	0.119x	-49.11%
2018-12-31	CN¥784.05 Million ≈ $114.73 Million	CN¥183.46 Million ≈ $26.85 Million	0.234x	+175.08%
2017-12-31	CN¥580.20 Million ≈ $84.90 Million	CN¥49.35 Million ≈ $7.22 Million	0.085x	+140.25%
2016-12-31	CN¥464.98 Million ≈ $68.04 Million	CN¥-98.26 Million ≈ $-14.38 Million	-0.211x	--

About Sirio Pharma

SHE:300791 China Packaged Foods

Market Cap

$773.49 Million

CN¥5.29 Billion CNY

Market Cap Rank

#9676 Global

#2415 in China

Share Price

CN¥17.20

Change (1 day)

+2.75%

52-Week Range

CN¥15.63 - CN¥25.86

All Time High

CN¥57.47